110 results about "Brain metastasis" patented technology

Two sets of genes and their encoded proteins, one set of 17 genes / proteins and one set of 18 genes / proteins that can be used in predicting the risk of cancer metastasis to the brain, and as a screening assay to identify the suitable treatments for brain metastases. Genes / proteins within the sets that are found to be differentially expressed relative to a control value are suitable targets for therapy.

Provided herein are methods, compositions and kits for the treatment of locally advanced or metastatic breast cancer or breast cancer brain metastases. The method comprises administration of 4-iodo-3-nitrobenzamide, a metabolite or salt thereof in combination with irinotecan. The method of treating locally advanced or metastatic breast cancer comprises at least one 21 day treatment cycle.

The present invention discloses a substituted quinazoline compound capable of crossing blood-brain barrier, wherein the structure formula of the compound is represented by a formula (I) defined in thespecification. According to the present invention, the substituted quinazoline compound, the derivative and the pharmaceutical salt thereof can unexpectedly cross blood-brain barrier, have the characteristics of drugs used as protein kinase inhibitors, are especially used for medical conditions mediated by the activation mutation forms of epidermal growth factor receptor, and can be used for treating or preventing disorders associated with abnormal protein kinase activity, wherein the disorders comprise cancers, cancer brain metastasis, cancer meningeal metastases, nerve center diseases and the like.

Disclosed are molecular diagnostic compositions and methods for predicting brain metastasis of breast cancer, as well as methods for drug repositioning to identify existing and new therapeutics for use in developing individualized, patient-specific treatment regimens for improving diagnoses and patient outcomes in individuals at risk for brain metastasis of breast cancer.

The invention discloses a Chinese herbal medicinal composition for treating lung cancer. Each dose of the composition at least comprises rehmannia, astragalus, Chinese angelica, ginseng, hoptoad, Indian iphigenia bulb, black nightshade herb, slug and barbated skullcup herb. The materials are added and reduced according to different stages of the lung cancer and different metastases of the lung cancer, and the composition can be prepared in different weight ratios into any formulation in pharmaceuticals . The composition is used for treating early stage of lung cancer, later stage of lung cancer, brain metastasis of the lung cancer, bilateral lung metastasis, bone metastasis, liver metastasis, adrenal gland metastasis and the like. Hundreds of cases of clinical practices prove that the Chinese herbal medicinal composition has remarkable curative effect on the lung cancer, and has longer surviving time than the third generation chemo-therapy medicament.

Methods and kits that use miRNA expression to predict the development of brain metastases in non-small cell lung cancer patients are disclosed.

The invention discloses BrBP1 polypeptide in specific binding with breast cancer brain metastases cells, and further relates to a preparation method of the polypeptide. The method includes: by utilization of phage display technology, carrying out a plurality of rounds of whole-cell depletion screening, and screening out phage clones bound with a breast cancer brain metastases cell line; randomly picking out a plurality of the phage clones, and selecting strongly positive phage clones with a cell enzyme-linked immuno sorbent assay (ELISA) method; and after increasing the strongly positive phage clones, carrying out sequencing, and synthesizing the tested BrBP1 polypeptide in a manual mode. The polypeptide can be applied to preparation of medicine used for curing breast cancer brain metastases and kits used for early-stage diagnosis of the breast cancer brain metastases. The polypeptide can be synthesized with a manual method, is small in molecular weight, high in activity, strong in penetrating power, high in affinity and specificity and low in toxicity, has good tumor-targeting performance inside and outside a body, can also be internalized to enter cells, and is suitable for being used as vectors for targeted therapy.

The invention discloses cyclic RNA circBCBM1 and a primer of the cyclic RNA circBCBM1 and the like in a PCR (Polymerase Chain Reaction) amplification process. The cyclic RNA has high expression in a breast cancer brain metastasis cell and has moderate and low expression in other breast cancer cells and normal cells, and sub-cells are positioned in cell nucleuses; the cyclic RNA circBCBM1 disclosedby the invention appears in the lacking of breast cancer brain metastasis related cyclic RNA at present for the first time; the cyclic RNA circBCBM1 disclosed by the invention has a wide applicationspace in the aspects of breast cancer brain metastasis risk predication and a clinical diagnosis molecular marker, and a target spot of researching and developing a novel breast cancer brain metastasis medicine.

The invention relates to application of a microRNA (Ribonucleic Acid) molecular expression profile for predicting non-small cell lung cancer brain metastasis risk, and in particular to application of one or more primers and / or probes for specifically detecting the microRNA molecular expression profile in preparing reagents for predicting the non-small cell lung cancer brain metastasis risk. The microRNA molecular expression profile comprises one or more of microRNA-193a-5p, microRNA-210, microRNA-214, microRNA-423-3p, microRNA-423-5p and microRNA-4270.

This invention relates to methods for using benzopyranones, or their pharaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis. The benzopyranones have the formula: wherein R1, R2, R3, n and p are as defined herein.

This invention is directed to a method to increased likelihood of brain metastasis from NSCLC in a subject by measuring the levels of LKB1. The invention also provides related kits.

The invention provides a microfluidic chip-based tumor brain metastasis model building method and use and belongs to the technical field of cytobiology and tissue engineering. The microfluidic chip comprises a waste liquid outlet, a cell inlet and a collagen inlet. The waste liquid outlet is communicated with the cell inlet through a two-dimensional passage. The collagen inlet is communicated with a three-dimensional passage. The junction of the two-dimensional passage and the three-dimensional passage forms a two dimensional-three dimensional microenvironment interface. The brain metastasis model building method utilizes the microfluidic chip and comprises 1, building a blood-brain barrier model through collagen perfusion into the chip and cell perfusion and culture on the chip, and 2, building a tumor brain metastasis model which is used for research on intracerebral metastasis of exogenous tumor cells and has characteristics of high throughput and high integrated level.

The invention belongs to the technical field of medicines and foods, relates to an enteric-coated microcapsule of an oily medicine or food, a preparation method and application thereof, in particular to the brucea javanica oil enteric-coated microcapsule, the preparation method and application thereof. The preparation method comprises the following steps: adding lecithin and an antioxidant to brucea javanica oil to absorb the oil to porous starch so as to obtain an oily soft material; adding an adhesive to the oily soft material, stirring at a high speed, granulating and then sieving to obtain a core material; and finally placing the core material in a bottom-spraying fluidized bed, and then spraying enteric-coated coating liquid to obtain the enteric-coated microcapsule. The brucea javanica oil enteric-coated microcapsule can conceal stench of the brucea javanica oil, avoid nausea and gastric stimulation, is easier to accept by patients, and has stability better than that of oral emulsion and more stable and regular drug release compared with single capsule; and the brucea javanica oil enteric-coated microcapsule and a further preparation thereof are applicable to treatment of various cancers such as lung cancer, brain metastasis, liver cancer and the like and adjunctive treatment after radiotherapy and chemotherapy.

Embodiments of the present invention concern methods related to treating, prognosticating and / or diagnosing at least brain metastatic breast cancer. Embodiments of the methods include characterizing circulating tumor cells for the presence or absence of EpCAM and, upon identification of EpCAM negative cells and identification of the status of other markers (such as heparanase and / or Notch1, for example), treating the individual based on the determination of the characterization.

The present invention relates to methods and compositions for determining whether a cancer patient is at increased risk for developing metastatic spread of the cancer and, if the patient is at increased risk, for treating the patient such that the risk of metastasis is reduced. It is based, at least in part, on the discoveries that overexpression of serpin and serpin secretion by cancer cells and L1CAM-mediated vascular cooption promote metastasis of lung and breast cancer to the brain, and that antagonism of serpin or L1CAM reduced metastasis.

The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.

The invention discloses an adjuvant therapeutic medicine composition, namely a brucea fruit oil dripping pill or an enteric dripping pill, for lung cancer, brain metastasis of lung cancer, digestive tract tumor and liver cancer, and a preparation method thereof. The preparation method is characterized in that brucea fruit oil is taken as a raw material and prepared into a dripping pill or the enteric dripping pill with a pharmaceutically acceptable substrate or a pharmaceutically acceptable additive, and each dripping pill or each enteric dripping pill contains 0.02 to 2 milliliters of the brucea fruit oil. The adjuvant therapeutic medicine composition improves the leachability of medicines, increases the stability of the medicines, reduces untoward reactions of the medicines, provides convenience for carrying and taking of the medicines, and is suitable for industrialized production.

Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein.

The present invention is concerned with the finding that some the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004 / 105765, is useful in the manufacture of a medicament for the treatment or prevention of a primary brain cancer or brain metastasis. It accordingly provides methods for treating, preventing, delaying or mitigating brain cancer, or for preventing or slowing proliferation of cells of brain origin.

The invention provides a microfluidic chip for constructing a bionic lung cancer brain metastasis model to solve the problem of the current difficulty in constructing a blood brain barrier for the lung cancer brain metastasis and incapability to achieve intuitive observation and the like. The microfluidic chip comprises a bionic lung portion and a bionic brain portion and is characterized in thatthe bionic lung portion is disposed on the upstream of the chip and comprises a three-layer structure including an upper substrate layer, an intermediate porous film layer and a lower substrate layer.The three-layer structure is provided with a gas channel, a liquid channel and a vacuum channel. The bionic brain portion is disposed on the downstream of the chip, and comprises a two-layer structure including an upper substrate layer and a lower substrate layer. The upper substrate layer is a cover layer. The lower substrate layer comprises a brain parenchyma chamber, and a blood brain barrierring is arranged outside the brain parenchyma chamber. A blood vessel cavity is arranged outside the blood brain barrier ring. The blood vessel cavity is connected with the liquid channel on the lowersubstrate layer of the bionic lung portion through a connecting channel. The blood brain barrier ring is provided with a micro gap structure communicated with the brain parenchyma chamber and the vascular chamber. The vascular chamber and the brain parenchyma chamber are provided with an inlet and an outlet for the liquid to flow in and out.

The invention relates to miRNA-based methods for prognosis of melanoma brain metastasis and related methods and kits. In one embodiment, the invention provides a method for predicting the likelihood of developing melanoma brain metastasis (B-Met) in a subject diagnosed with primary melanoma, said method comprising determining the levels of miR-150-5p, miR-15b-5p, miR-16-5p, and miR-374b-3p in a primary melanoma sample collected from the subject.

The present disclosure relates to an EpCAM aptamer or an EpCAM aptamer conjugate having bi-functional activity and to uses thereof. In particular, the present disclosure also relates to an aptamer conjugate which binds to the transferrin receptor (TfR) and EpCAM which is useful for treatment of brain tumours and / or brain metastasis.

The invention discloses a miRNA composition for detecting breast cancer brain metastases and a kit with same. The miRNA composition comprises miR-10b and one or more of miR-200a, miR-122, miR-21 and miR-181c. The kit comprises forward and reverse primers of the miRNA composition, forward and reverse primers of an external reference U6 RNA, a cerebrospinal fluid RNA extraction system, a reverse transcription reagent, a PCR amplification reagent and a cDNA mixed positive reference product. According to the miRNA composition, a group of miRNAs are adopted as novel breast cancer brain metastases markers, low specificity and low sensitivity caused by tumor heterogeneity are hard to overcome by using a single marker can be alleviated, prognosis effectiveness evaluation of a patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed. The miRNA composition is used for preparing a kit or a biological chip for prognosis inspection on breast cancer by using a fluorescent quantitative / digital PCR method, low specificity and low sensitivity caused by tumor heterogeneity can be avoided, the prognosis effectiveness evaluation of the patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed.

The invention discloses a 5-substituted difluoro piperidine compound capable of penetrating blood brain barrier, wherein the compound has a structural formula represented by a formula (I). According to the present invention, the 5-substituted difluoro piperidine compound, the derivative and the pharmaceutical salt thereof can unexpectedly penetrate blood brain barrier, can have the pharmaceuticalproperties of protein kinase inhibitors, can particularly treat vascular endothelial growth factor receptor 2 or SRC kinase family (FYN)-mediated medical conditions, can further be used for treating or preventing abnormal protein kinase activity related disorders such as cancer, cancer brain metastasis, primary brain cancers such as glioma, malignant glioma, cancer meningeal metastasis, Alzheimer's disease, neurological diseases and the like.

The present invention provides for the treatment of a subject with occult brain metastasis. The treatment relies on administering to the subject a composition comprising an immunomodulatory polypeptide and a baculovirus-insect cell preparation. This composition has a unique ability to generate an anti-tumor immune response that is able to cross the blood-brain barrier.

A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.

The invention provides a non-small cell lung cancer brain metastases prediction device which consists of five concentric circles and a pointer with an arrow, wherein the five concentric circles and the pointer are fixed through metal rivets by sharing the same center to form a compass shape; postoperative pathological parameters of tumor patients, such as tumor types, differentiation degree and lymph gland states, are respectively marked on the concentric circles. The risk of non-small cell lung cancer brain metastases is evaluated by utilizing the state of a tumor marker NSE. The device is reasonable in design, is displayed in an intuitive compass form, and can be used for guiding a clinicist to estimate the prognostic risk of brain metastases of the patient, perform early interventional treatment on a patient with high risk and select an optimal comprehensive treatment scheme for the patient; meanwhile, the postoperative monitoring strategy can be perfected, the reexamination frequency is increased, the brain imaging check is emphasized, and the device provides help for timely discovering the brain metastases.

The invention discloses a pyrazole quinazolinone derivative serving as a PARP (poly ADP-ribose polymerase) inhibitor and application of the pyrazole quinazolinone derivative serving as the PARP inhibitor. The pyrazole quinazolinone derivative serving as the PARP inhibitor refers to a compound in a formula (I) as shown in the specification or pharmaceutically acceptable salts of the compound. The compound can be used as the PARP inhibitor, has great PARP-1 inhibition activity and can serve as a selective inhibitor for prevention and treatment of PARP related diseases. The compound further has agreat characteristic of blood-brain-barrier penetrating and has a promising application prospect in prevention and treatment of brain metastasis of brain tumors and other tumors.

The invention provides a late breast cancer survival probability prediction nomogram, a survival probability determination method and a patient classification method. The nomogram comprises a score scale and a plurality of prognostic variables, and the prognostic variables are classification variables and comprise a breast cancer staging variable, a breast cancer molecular typing variable, a patient disease-free recurrence time variable, a tumor load variable and a brain metastasis variable; each prognostic variable comprises a plurality of variable values, and each variable value correspondsto one score on the score scale; the nomogram also comprises a total score scale and patient survival probability variables which are continuous variables and comprise a one-year survival probabilityvariable, a two-year survival probability variable and a three-year survival probability variable, wherein each survival probability variable comprises a variable value range, and each variable valuerange has a score range corresponding to the total score scale; the development of medical science is considered, and meanwhile, the requirements of domestic patients are considered, so that the evaluation accuracy of the advanced breast cancer is improved.